Form 4: ADMA Biologics Director, Young Kwon, Reports Acquisition of Shares and Stock Options

Director Young Kwon reports acquisition of ADMA Biologics shares and stock options through restricted stock units and option grants.

Summary

• On February 19, 2025, Young Kwon, a director of ADMA Biologics, acquired 10,889 shares of common stock through restricted stock units (RSUs).
• These RSUs will vest in two equal installments over six and twelve months from the grant date.
• Kwon also acquired 16,279 stock options with an exercise price of $16.07, vesting monthly over one year and expiring on February 19, 2035.
• Following these transactions, Kwon directly owns 252,330 shares of common stock, including the newly granted RSUs, and 16,279 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider transactions. The acquisition of shares and options by a director is generally viewed positively, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

ADMA Biologics, Young Kwon, Form 4, Beneficial Ownership, Stock Options, RSUs, Director, Shares